Oct 18 (Reuters) - Halozyme Therapeutics , which specializes in reformulating drug products available only as infusions, said a pivotal trial of subcutaneous Herceptin, the cancer drug sold by Roche , ...
Halozyme Therapeutics announced positive results from its Phase 3 HannaH study of subcutaneous (SC) Herceptin (trastuzumab) for the treatment of HER2-positive early breast cancer. HannaH is an ...
— Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment — — Phase III FeDeriCa ...
Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs1,2,3 Treatment with Phesgo is over 90% faster, ...
Shares of Halozyme Therapeutics Inc. jumped 18.6 percent Tuesday on news that its subcutaneous version of HER2-positive breast cancer drug Herceptin (trastuzumab) was comparable to the marketed ...
Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment US Food Drug and ...
The restructuring of the company post PEGPH20 failure and prioritization of Enhanze business is a solid positive for Halozyme. Commercial launch of Darzalex SC and Perjeta/Herceptin FC subcutaneous ...
SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that new data from the global phase III FeDeriCa study conducted by Genentech, a member of the Roche ...
Trastuzumab 600mg, hyaluronidase-oysk 10000 Units; per 5mL; soln for SC inj; preservative-free. Store vials in the refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback